文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > Printed in Great Britain The Company of Biologists Limited
侵权投诉

Printed in Great Britain The Company of Biologists Limited

Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy

Journal of Cell Science 112, 1733-1741 (1999)

Printed in Great Britain ©The Company of Biologists Limited 1999JCS0216

1733

Activation-dependent clustering of the erbB2 receptor tyrosine kinasedetected by scanning near- eld optical microscopy

Péter Nagy1,2,*, Attila Jenei1,2, Achim K. Kirsch1, János Szöllo si2, Sándor Damjanovich2and Thomas M. Jovin1,

1Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, D-37077 Göttingen, Germany2Department of Biophysics and Cell Biology, University Medical School of Debrecen, Nagyerdei krt. 98, PO Box 39, H-4012

Debrecen, Hungary

*Biophysical Research Group of the Hungarian Academy of Sciences, University Medical School of Debrecen Author for correspondence (e-mail: tjovin@mpc186.mpibpc.gwdg.de)

Accepted 17 March; published on WWW 11 May 1999

SUMMARY

ErbB2 (HER2, Neu), a member of the epidermal growthfactor (EGF) receptor tyrosine kinase family, is oftenoverexpressed in breast cancer and other malignancies.ErbB2 homodimerizes but also presents as a commonauxiliary subunit of the EGF and heregulin receptors(erbB1 or EGFR; and erbB3-4, respectively), with which itheteroassociates. ErbB2 is generally regarded as an orphan(ligand-less) receptor with a very potent kinase domainactivated either via its associated partners or constitutivelyas a consequence of discrete mutations. It follows that theextent and regulation of its cell surface interactions are ofcentral importance. We have studied the large-scaleassociation pattern of erbB2 in quiescent and activated cellslabeled with uorescent anti-erbB2 monoclonal antibodiesusing scanning near- eld optical microscopy (SNOM).ErbB2 was found to be concentrated in irregularmembrane patches with a mean diameter of approx. 0.5 µm

in nonactivated SKBR3 and MDA453 human breast tumorcells. The average number of erbB2 proteins in a singlecluster on nonactivated SKBR3 cells was about 103.Activation of SKBR3 cells with EGF, heregulin as well as apartially agonistic anti-erbB2 monoclonal antibody led toan increase in the mean cluster diameter to 0.6-0.9 µm,irrespective of the ligand. The EGF-induced increase in theerbB2 cluster size was inhibited by the EGFR-speci ctyrosine kinase inhibitor PD153035. The average size oferbB2 clusters on the erbB2-transfectedline of CHO cells(CB2) was similar to that of activated SKBR3 cells, a nding correlated with the increased base-line tyrosinephosphorylation of erbB2 in cells expressing only erbB2.We conclude that an increase in cluster size may constitutea general phenomenon in the activation of erbB2.

Key words: ErbB2; EGF receptor; Homassociation; SNOM; NSOM

INTRODUCTION

ErbB2 is a member of the epidermal growth factor receptor(EGFR) family of transmembrane receptor tyrosine kinases(Alroy and Yarden, 1997; Hynes and Stern, 1994). Althoughithas no known ligand, it is commonly found inheteroassociation with the other three members of the erbBfamily, speci cally the EGF (erbB1) and heregulin (erbB3,erbB4) receptors (Karunagaran et al., 1996). The interactionwith erbB2 greatly enhances the signaling capacity of theseproteins (Tzahar et al., 1996). Mutant forms of erbB2 arehighly oncogenic due to the constitutive activation of its verypotent kinase activity (Bargmann et al., 1986). The effects ofoncogenic erbB2 on the malignant phenotype are alsodetermined by the nature of the homo- and heterodimers thatform in the context of a given expression pattern. ErbB2 isoverexpressed in breast cancer patients (Ahmad et al., 1993).However, considerable controversy exists about the prognosticvalue of this nding, attributable at least in part to differencesin the binding speci cities and affinities of the monoclonal andpolyclonal antibodies used in clinical laboratory practice (Presset al., 1994; Strawn and Shawver, 1998). The importance ofsmall- and large-scale clustering of receptors in determiningthe malignant phenotype was not addressed in these studies. Ahumanized monoclonal antibody against erbB2 has been inclinical trial (Baselga et al., 1996) and just approved for patientuse.

The association of erbB receptor molecules has beenexamined extensively by classical biochemical, molecularbiological (Sliwkowski et al., 1994; Tzahar et al., 1996) andbiophysical (Gadella and Jovin, 1995; Nagy et al., 1998)techniques. Biochemical methods revealed that extensivehomo- and heteroassociation is present among members of theerbB family (Tzahar et al., 1996), but since these methodsnecessitate the isolation of proteins, they are inherently unableto detect the association in the in vivo environment, and arealso not suitable for detecting heterogeneity within or amongcells. Fluorescence resonance energy transfer (FRET) has beenused to measure the monomer-dimer distribution of EGF(erbB1) receptors in living cells (Gadella and Jovin, 1995), as

第1页

TOP相关主题

你可能喜欢

热门文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email